Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04938986
Recruiting Not applicable

Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer

NCT04938986 · tracked via the Priya Life Science France tracker
Sponsor
Hospital St. Joseph, Marseille, France
Phase
Not applicable
Started
2022-04-04
Last updated
2022-04-13

Condition(s) studied

Non Metastatic Colorectal Cancer

Investigational drug(s) / intervention(s)

IMMUNOSCORE®

IMMUNOSCORE®: recommendation for patient care according to the result of the IMMUNOSCORE®

Study summary

Evaluate the patient care recommandation induced by the IMMUNOSCORE® result

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * age between 18 and 80 inclusive; * histologically confirmed colon adenocarcinoma; * having undergone a curative resection of stage I, II or III colorectal cancer; * diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2; * eligible to receive 6 months of adjuvant chemotherapy; * having given free, informed and written consent; * agreeing to the use of a tumor sample for research purposes; * being affiliated to a social security system. Exclusion Criteria: * pregnant or breastfeeding women * legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study. * history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled * person subject to a safeguard measure.

Primary outcome measure(s)

  • Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision — 5 years

Trial sites (2)

FacilityCityRegionStatus
Hôpital Européen Marseille France Not Yet Recruiting
Hopital Saint Joseph Marseille France Recruiting

More Hospital St. Joseph, Marseille, France trials in France

Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers Recruiting
Feasibility of Molecular Biology in Pancreatic Cyst Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04938986 on ClinicalTrials.gov ↗ ← All trials in France